PB6440
AssetAlso called SE-6440, VT-6440
Selectively inhibits aldosterone synthase to reduce aldosterone production and lower blood pressure.
- Stage
- Preclinical, no development reported
- Modality
- Small molecule
- Target
- CYP11B2
- 1
- Indication
- 0
- Trials
- 1
- Developer
No development reported since January 2020. Last activity: Development reported. SEC filing
Indications
1Treatment-resistant hypertension
Preclinical, SEC filing, Jan 13, 2020
In the full profile
- Target and mechanism1
- Owner and partners3
- Evidence for its targets1
- Competitors4
Every asset’s record: target, stage, trials and the evidence behind it.